The prospectus for Brighter’s rights issue is now available

The prospectus that has been produced on the basis of the rights issue initially announced on November 18, and changed earlier today, has now been approved and registered by the Swedish Financial Supervisory Authority. The prospectus will be available on the company's website.

The prospectus states that trading in BTA begins on December 13, 2019, which is incorrect. Trading in BTA will begin on December 18, 2019.

For further information, please contact:

The Board of Directors: styrelsen@brighter.se

Ann Zetterberg, CFO
Phone: +46 708 37 21 23
Email: ann.zetterberg@brighter.se

Henrik Norström, CEO  
Phone: +46 733 40 30 45     
Email: henrik.norstrom@brighter.se

About Brighter AB (publ)

Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. https://brighter.se/

The Company's shares are listed on Nasdaq First North Growth Market/BRIG. Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, adviser@eminova.se, www.eminova.se.